Topical alprostadil cream for the treatment of erectile dysfunction

Bibliography

• LAUMANN EO, PAIK A, ROSEN RC: Sexual dysfunction in the United States: prevalence and predictors. JAMA (1999) 281:537–544.
   PubMed Web of Science ®Google Scholar
• PENSON DF, LATINI DM, LUBECK DP, WALLACE K, HENNING JM, LUE T: Isquality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the ExCEED data base. Um] (2003) 169(4):1458–1461.
   Google Scholar
• BRAUN M, WASSMER G, KLOTZ T, REIFENRATH B, MATHERS M, ENGELMANN U: Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int. Impel-. Res. (2000) 12(6):305–311.
   PubMed Web of Science ®Google Scholar
• STOLK EA, BUSSCHBACH JJ: Are patients and the general public like-minded about the effect of erectile dysfunction on quality of life?aUrology (2003) 61(4):810–815.
   Google Scholar
• LATINI DM, PENSON DF, LUBECK DP, WALLACE KL, HENNING JM, LUE TF:Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction study. Um] (2003) 169(4):1437–1442.
   Google Scholar
• NIH CONSENSUS DEVELOPMENTPANEL ON IMPOTENCE: Impotence. NIH Consensus Conference. JAMA (1993) 270:83–90.
   Google Scholar
• TAN JK, HONG CY, PNG DJ, LIEW LC, WONG ML: Erectile dysfunction in Singapore: prevalence and its associated factors - a population-based study.Singapore. Med. (2003) 44(1):20–26.
   Google Scholar
• READ S, KING M, WATSON J: Sexual dysfunction in primary medical care: prevalence, characteristics and detection by the general practitioner. Public. Health. Med. (1997) 19(4):387–391.
   PubMedGoogle Scholar
• BACON CG, MITTLEMAN MA, KAWACHI I, GIOCANNUCCI E, GLASSER DB, RIMM EB: Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann. Intern. Med. (2003) 139(3):161–168.16. CHEW KK, EARLE CM, STUCKEY BG, JAMROZOK K, KEOGH EJ: Erectile dysfunction in general medicine practice: prevalence and clinical correlates.Int. Layer Res. (2000) 12(1):41–45.
   Google Scholar
• FELDMAN HA, GOLDSTEIN I, HATZICHRISTOU DG, KRANE RJ, MCKINLAY JB: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study.J. Um] (1994) 151(1):54–61.
   Google Scholar
• NOLAZCO C, BELLORA 0, LOPEZ M et al.: Prevalence of sexual dysfunctions in Argentina. Int. .1. Impel-. Res. (2004) 16(1):69–72.
   Google Scholar
• MONTORSI F, BRIGANTI A,SALONIA A et al: Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease.Eur. Ural. (2003) 44(3):360–364; Discussion: 364–365.
   Google Scholar
• SAENZ DE TEJADA I: Molecular mechanisms for the regulation of penile smooth muscle contractility. Int. .1 Irnpot. Res. (2002) 14\(Suppl. 1):56–S10.
   Google Scholar
• LUE TF: Erectile dysfunction. N Engl. Med. (2000) 342(24):1802–1813.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of ED and it's treatment.
   Google Scholar
• SULLIVAN ME, KEOGHANE SR, MILLER MA: Vascular risk factors and erectile dysfunction. RIU Int. (2001) 87(9):838–845.
   Google Scholar
• MONTORSI F, SALONIA A, DEHO' F et al: Pharmacological management of erectile dysfunction. RIU Int. (2003) 91 (5):446–454.
   Google Scholar
• BRINDLEY GS: Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence.Br.Psychiatry (1983) 143:332–337.
   PubMed Web of Science ®Google Scholar
• VIRAG R: Intracavernous injection of papaverine for erectile failure.Lancet (1982) 2(8304):938.
   PubMedGoogle Scholar
• ANDERSSON KE: Pharmacology of penile erection. Pharmacy] Rev (2001)53 (3):417–450.
   PubMed Web of Science ®Google Scholar
• BENNETT AH, CARPENTER AJ, BARADA JH: An improved vasoactive drugcombination for a pharmacological erection program.' Urol. (1991) 146:1564.
   PubMed Web of Science ®Google Scholar
• LINET OI, OGRINC FG: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl. J. Med. (1996) 334(14):873–877.
   PubMed Web of Science ®Google Scholar
• •Important intracavernosal safety and efficacy report.
   Google Scholar
• PADMA-NATHAN H, HELLSTROM WJ, KAISER FE et al: Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl. J. Med. (1997) 336(1):1–7.
   PubMed Web of Science ®Google Scholar
• •Important transurethral safety and efficacy report.
   Google Scholar
• Vivus, Inc.: MUSE package insert. Vivus, Inc., Mountain View, CA, USA (2003).
   Google Scholar
• WILLIAMS G, ABBOU CC, AMAR ET et al.: Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br: J. Urol. (1998) 81(6):889–894.
   PubMedGoogle Scholar
• •Important transurethral safety and efficacy report.
   Google Scholar
• BECHER E, TEJADA NORIEGA A, GOMEZ R, DECIA R. Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. Int. J. Impor Res. (2002)14\(Suppl. 2):533–541.
   Google Scholar
• GRESSER U, GLEITER CH: Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. Eur: J. Med. Res. (2002) 7(10):435–446.
   PubMed Web of Science ®Google Scholar
• CARSON CC: Long-term use of sildenafil. Expert. Opin. Pharmacother. (2003) 4(3):397–405.
   PubMedGoogle Scholar
• Pfizer, Inc.: Viagra® (sildenafil citrate) package insert. Pfizer, Inc., New York, NY, USA (2003).
   Google Scholar
• KIM S, NARAYANAN S, SONG JC: Tadalafil. Formulary(2002) 37:289–296.
   Google Scholar
• Bayer Pharmaceuticals Corporation: Levitra® (vardenafil) package insert. Bayer Pharmaceuticals Corporation, West Haven, CT, USA (2003).
   Google Scholar
• PRYOR JL, REDMON B. New therapies and delivery mechanisms for treatment of erectile dysfunction. Int. J. Impot. Res. (2000) 12\(Suppl. 4):5158–5162.
   Google Scholar
• BOYUKTIMKIN N, BOYUKTIMKIN S, RYTTING JH: Alky-N,N-disubstituted amino acetates. In: Percutaneous penetration enhancers. Smith E, Maibach HI (Eds), CRC Press, Boca Raton, FL, USA (1995) Chapter 4.2.
   Google Scholar
• BOYUKTIMKIN N, BOYUKTIMKIN S, RYTTING JH: (1997) Chemical means of transdermal drug permeation enhancement. In: Transdermal and Topical Drug Delivery Systems. Ghosh TK, Pfister WR, Yum SI (Eds), Interpharm Press, Englewood, CO, USA (1997).
   Google Scholar
• BEIHN RM: Gamma scintigraphy measurement of the retention and migration of an erectile dysfunction topical formulation applied to the tip of the human male penis. Data on file at NexMed (USA), Inc.; Protocol No. NEXSCIN 2001–001; US IND No 53,953; 2002.
   Google Scholar
• ADAIKAN PG, KOTTEGODA SR, RATNAM SS. A possible role for prostaglandin El in human penile erection. Proceedings of the Second World Meeting on Impotence, Prague, Czechoslovakia (1986) Abstract 2.6.
   Google Scholar
• PALMER LS, VALCIC M, MELMAN A, GIRALDI A, WAGNER G, CHRIST GJ: Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells.Urol. (1994) 152(4):1308–1314.
   Google Scholar
• TRAISH AM, MORELAND RB, GALLANT C, HUANG YH, GOLDSTEIN I: G-protein-coupled receptor agonists augment adenylyl cyclase activity induced by forskolin in human corpus cavernosum smooth muscle cells. Recept. Signal. Transduct. (1997) 7(2):121–132.
   PubMedGoogle Scholar
• VARDI Y, SAENZ DE TEJADA I: Functional and radiologic evidence of vascular communication between the spongiosal and cavernosal compartments of the penis. Urology (1997) 49(5):749–752.
   PubMedGoogle Scholar
• HALATA Z, MUNGER BL: The neuroanatomical basis for the protopathic sensibility of the human glans penis. Brain. Res. (1986) 371(2):205–230.
   PubMed Web of Science ®Google Scholar
• OKADA K: The mechanism of action of Alprox-TD. Presented at: The Management of Male Sexual Dysfunction. Monte Carlo, Monaco (2002).
   Google Scholar
• BECHER E, BORGHI M, MOMESSO A, MONTES DE OCA L: Penile Hemodynamic findings with a new topical formulation of alprostadil. Urol. (1998) 159\(Suppl. 2):239 (Abstact 915).
   Google Scholar
• BECHER E, BORGHI M, MONTES DE OCA L, MOMESSO A: Enhancement of the glans engorgement in patients with penile implants using topical alprostadil. Int. J. Impot. Res. (2002) 14\(Suppl. 3):598.
   Google Scholar
• •Haemodynarnic evidence of smooth muscle relaxation using the transdermal route.
   Google Scholar
• BENEVIDES MD, CARSON CC: Intraurethral application of alprostadil in patients with failed inflatable penile prosthesis. J. Urol. (2000) 163(3):785–787.
   PubMedGoogle Scholar
• PADMA-NATHAN H, STEIDLE C, SALEM S, TAYSE N, YEAGER J, HARNING R: The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two Phase II studies in mild-to-moderate and severe ED. Int. j Impor Res. (2003) 15(1):10–17.
   PubMed Web of Science ®Google Scholar
• •Safety, and efficacy of topical alprostadil cream in patients with mild-to-moderate and severe ED.
   Google Scholar
• STEIDLE C, PADMA-NATHAN H, SALEM S et al.: Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the Phase II program. Urology (2002) 60(6):1077–1082.
   PubMedGoogle Scholar
• •First report of safety and efficacy of topical alprostadil cream.
   Google Scholar
• STEERS WD: Viability and safety ofcombination drug therapies for erectile dysfunction. J. Urol. (2003)170(2 Pt 2):S20-S30.Patents
   Google Scholar
• BOYOKTIMKIN S, BOYOKTIMKIN N, YEAGER JL: U56046244 (2000).
   Google Scholar
• BOYOKTIMKIN S, BOYOKTIMKIN N: U56118020 (2000).
   Google Scholar
• YEAGER J, BOYOKTIMKIN A, BOYOKTIMKIN S: U56323241B1 (2001).
   Google Scholar
• http://www.bayerpharma-na.com/ news/co0272.asp.Bayer Pharmaceutical Division, North America: Major Multinational Male Health Survey findings, support the need for new treatment options for the improvement of erectile function. Accessed October 2 (2003).
   Google Scholar